CA2171276C - Utilisation d'un antagoniste de recepteur d'interleukine-1 recombinant humain; composition renfermant cet antagoniste pour le traitement de l'arthrose - Google Patents

Utilisation d'un antagoniste de recepteur d'interleukine-1 recombinant humain; composition renfermant cet antagoniste pour le traitement de l'arthrose Download PDF

Info

Publication number
CA2171276C
CA2171276C CA002171276A CA2171276A CA2171276C CA 2171276 C CA2171276 C CA 2171276C CA 002171276 A CA002171276 A CA 002171276A CA 2171276 A CA2171276 A CA 2171276A CA 2171276 C CA2171276 C CA 2171276C
Authority
CA
Canada
Prior art keywords
osteoarthritis
receptor antagonist
cartilage
human recombinant
recombinant interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002171276A
Other languages
English (en)
Other versions
CA2171276A1 (fr
Inventor
Jean-Pierre Pelletier
Johanne Martel-Pelletier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascentia Pharma Inc
Original Assignee
Ascentia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascentia Pharma Inc filed Critical Ascentia Pharma Inc
Priority to CA002171276A priority Critical patent/CA2171276C/fr
Publication of CA2171276A1 publication Critical patent/CA2171276A1/fr
Application granted granted Critical
Publication of CA2171276C publication Critical patent/CA2171276C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
CA002171276A 1996-03-07 1996-03-07 Utilisation d'un antagoniste de recepteur d'interleukine-1 recombinant humain; composition renfermant cet antagoniste pour le traitement de l'arthrose Expired - Fee Related CA2171276C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002171276A CA2171276C (fr) 1996-03-07 1996-03-07 Utilisation d'un antagoniste de recepteur d'interleukine-1 recombinant humain; composition renfermant cet antagoniste pour le traitement de l'arthrose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002171276A CA2171276C (fr) 1996-03-07 1996-03-07 Utilisation d'un antagoniste de recepteur d'interleukine-1 recombinant humain; composition renfermant cet antagoniste pour le traitement de l'arthrose

Publications (2)

Publication Number Publication Date
CA2171276A1 CA2171276A1 (fr) 1997-09-08
CA2171276C true CA2171276C (fr) 2006-05-16

Family

ID=4157707

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002171276A Expired - Fee Related CA2171276C (fr) 1996-03-07 1996-03-07 Utilisation d'un antagoniste de recepteur d'interleukine-1 recombinant humain; composition renfermant cet antagoniste pour le traitement de l'arthrose

Country Status (1)

Country Link
CA (1) CA2171276C (fr)

Also Published As

Publication number Publication date
CA2171276A1 (fr) 1997-09-08

Similar Documents

Publication Publication Date Title
Caron et al. Chondroprotective effect of intraarticular injections of interleukin‐1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase‐1 expression
Pelletier et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase
US5972880A (en) Method of treatment of osteoarthritis with interleuken-1 receptor antagonist
US6190704B1 (en) Regulation of wound healing by nitric oxide
Yoshioka et al. The effects of hyaluronan during the development of osteoarthritis
Moore et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis
Fernandes et al. Effects of Tenidap on canine experimental osteoarthritis I. Morphologic and metalloprotease analysis
JP6208763B2 (ja) 変形性関節症を治療するためのｐｅｄｆ−由来のポリペプチドの使用
Lan et al. Expression of Notch signaling pathway during osteoarthritis in the temporomandibular joint
AU2019383576A1 (en) Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
Aulin et al. An in vivo cross-linkable hyaluronan gel with inherent anti-inflammatory properties reduces OA cartilage destruction in female mice subjected to cruciate ligament transection
JP2024054274A (ja) 変形性関節症の治療におけるｐｅｄｆ由来短鎖ペプチドの使用
US6653350B1 (en) Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
CA2171276C (fr) Utilisation d'un antagoniste de recepteur d'interleukine-1 recombinant humain; composition renfermant cet antagoniste pour le traitement de l'arthrose
Wu et al. Effect of dehydroepiandrosterone on cartilage and synovium of knee joints with osteoarthritis in rabbits
Garr et al. Degenerative changes following experimental patellectomy in the rabbit.
Fu et al. Erythropoietin enhances meniscal regeneration and prevents osteoarthritis formation in mice
Wegner et al. The effect of losartan on the development of post-traumatic joint stiffness in a rat model
Choi et al. Anti-osteoarthritic effects of a combination of pomegranate concentrate powder, Eucommiae cortex and Achyranthis radix in rats
Sridharan et al. Polyacrylic acid attenuates ethylene glycol induced hyperoxaluric damage and prevents crystal aggregation in vitro and in vivo
Piller The action of the benzopyrones on an experimental model of lymphoedema: a contribution to their mode of action.
EP1041997B1 (fr) Utilisation de peptides citrullines derives de la filaggrine dans le cadre du traitement de maladies autoimmunes
US20220387556A1 (en) Use of the gdf-5 mutant for the treatment of pain and cartilage destruction
EP4360627A1 (fr) Traitement de l'arthrose par des inhibiteurs de comt
Schulze et al. Genital Lichen Sclerosus (Balanitis Xerotica Obliterans): BXO

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed